Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics (2024)
- Authors:
- USP affiliated authors: SANTOS, RAFAEL GUIMARÃES DOS - FMRP ; HALLAK, JAIME EDUARDO CECILIO - FMRP
- Unidade: FMRP
- DOI: 10.3389/fpsyt.2024.1485337
- Subjects: FÁRMACOS PSICOTRÓPICOS; ALUCINOGÊNICOS; NEUROTRANSMISSORES; SEROTONINA
- Keywords: Dimethyltryptamine (DMT); Ayahuasca; Psychedelics; Hallucinogen; Neuroplasticity; Sigma-1 receptor; Serotonin 2A (5HT2A) receptor; Pharmacology
- Language: Inglês
- Imprenta:
- Source:
- Título: Frontiers in Psychiatry
- ISSN: 1664-0640
- Volume/Número/Paginação/Ano: v. 15, art. 1485337, p. 1-8, 2024
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by
-
ABNT
CHAVES, Cristiano et al. Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics. Frontiers in Psychiatry, v. 15, p. 1-8, 2024Tradução . . Disponível em: https://doi.org/10.3389/fpsyt.2024.1485337. Acesso em: 09 jan. 2026. -
APA
Chaves, C., Santos, R. G. dos, Dursun, S. M., Tusconi, M., Carta, M. G., Brietzke, E., & Hallak, J. E. C. (2024). Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics. Frontiers in Psychiatry, 15, 1-8. doi:10.3389/fpsyt.2024.1485337 -
NLM
Chaves C, Santos RG dos, Dursun SM, Tusconi M, Carta MG, Brietzke E, Hallak JEC. Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics [Internet]. Frontiers in Psychiatry. 2024 ; 15 1-8.[citado 2026 jan. 09 ] Available from: https://doi.org/10.3389/fpsyt.2024.1485337 -
Vancouver
Chaves C, Santos RG dos, Dursun SM, Tusconi M, Carta MG, Brietzke E, Hallak JEC. Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics [Internet]. Frontiers in Psychiatry. 2024 ; 15 1-8.[citado 2026 jan. 09 ] Available from: https://doi.org/10.3389/fpsyt.2024.1485337 - Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer
- Polypharmacology or “pharmacological promiscuity” in psychedelic research: what are we missing?
- Risk assessment of ayahuasca use in a religious context: self-reported risk factors and adverse effects
- Hallucinogens/psychedelics resurrected as new tools in psychiatric therapy [Editorial]
- Natural hallucinogens in mental health [Editorial]
- Ayahuasca and Public Health II: health status in a large sample of ayahuasca-ceremony participants in the Netherlands
- Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: evidence and mechanisms of action
- Underground ibogaine use for the treatment of substance use disorders: aqualitative analysis of subjective experiences
- Ayahuasca-enhanced extinction of fear behaviour: role ofinfralimbic cortex 5-HT 2A and 5-HT 1A receptors
- Therapeutic use of serotoninergic hallucinogens: a review of the evidence and of the biological and psychological mechanisms
Informações sobre o DOI: 10.3389/fpsyt.2024.1485337 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003249584.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
